T-switch-ing TCR specificity

Andrew Y Hu¹, Cristina Puig-Saus²

Affiliations

¹ Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA, USA; Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA, USA.
² Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA, USA; Department of Microbiology, Immunology, and Molecular Genetics at the University of California Los Angeles (UCLA), Los Angeles, CA, USA; Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center-UCLA, Los Angeles, CA, USA; Broad Stem Cell Research Center-UCLA, Los Angeles, CA, USA. Electronic address: cpuigsaus@mednet.ucla.edu.

PMID: 39662088
DOI: 10.1016/j.immuni.2024.11.014

Comment

T-switch-ing TCR specificity

Andrew Y Hu et al. Immunity. 2024.

. 2024 Dec 10;57(12):2717-2719.

doi: 10.1016/j.immuni.2024.11.014.

Authors

Andrew Y Hu¹, Cristina Puig-Saus²

Affiliations

¹ Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA, USA; Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA, USA.
² Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine at the University of California Los Angeles (UCLA), Los Angeles, CA, USA; Department of Microbiology, Immunology, and Molecular Genetics at the University of California Los Angeles (UCLA), Los Angeles, CA, USA; Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center-UCLA, Los Angeles, CA, USA; Broad Stem Cell Research Center-UCLA, Los Angeles, CA, USA. Electronic address: cpuigsaus@mednet.ucla.edu.

PMID: 39662088
DOI: 10.1016/j.immuni.2024.11.014

Abstract

Central tolerance restricts T cells that target self-antigens. In this issue of Immunity, Abdelfattah et al.¹ describe a method to generate self-reactive T cell receptors (TCRs) by directed evolution of non-autoreactive TCRs to recognize self-antigen peptides and demonstrate potential for T cells engineered with such receptors in immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests C.P.-S. has received honoraria and consulting fees from ImmPACT Bio, Merck, and Kyowa Kirin and is a co-founder and stockholder of ImmPACT Bio. C.P.-S. and A.Y.H. are inventors of several cell therapy patent applications.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

T-switch-ing TCR specificity

Affiliations

T-switch-ing TCR specificity

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources